AU2005316561A1 - The uses of estrogen beta agonists to treat cognitive diseases - Google Patents
The uses of estrogen beta agonists to treat cognitive diseases Download PDFInfo
- Publication number
- AU2005316561A1 AU2005316561A1 AU2005316561A AU2005316561A AU2005316561A1 AU 2005316561 A1 AU2005316561 A1 AU 2005316561A1 AU 2005316561 A AU2005316561 A AU 2005316561A AU 2005316561 A AU2005316561 A AU 2005316561A AU 2005316561 A1 AU2005316561 A1 AU 2005316561A1
- Authority
- AU
- Australia
- Prior art keywords
- carbon atoms
- alkyl
- halogen
- alkenyl
- hydroxyphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/055—Phenols the aromatic ring being substituted by halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63714404P | 2004-12-17 | 2004-12-17 | |
| US60/637,144 | 2004-12-17 | ||
| PCT/US2005/045375 WO2006065968A2 (en) | 2004-12-17 | 2005-12-15 | The uses of estrogen beta agonists to treat cognitive diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2005316561A1 true AU2005316561A1 (en) | 2006-06-22 |
Family
ID=36143266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005316561A Abandoned AU2005316561A1 (en) | 2004-12-17 | 2005-12-15 | The uses of estrogen beta agonists to treat cognitive diseases |
Country Status (20)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1984028A2 (en) * | 2006-02-14 | 2008-10-29 | Wyeth a Corporation of the State of Delaware | Aqueous pharmaceutical formulations of er selective ligands |
| WO2010105035A2 (en) * | 2009-03-11 | 2010-09-16 | University Of South Florida | Prevention, treatment, and diagnosis of alzheimer's disease through electromagnetic field exposure |
| US10149982B2 (en) | 2009-03-11 | 2018-12-11 | University Of South Florida | Prevention and treatment of brain diseases and disorders related to abnormal protein aggregation through electromagnetic field treatment |
| US10758496B2 (en) * | 2014-09-02 | 2020-09-01 | The Regents Of The University Of California | Estrogen receptor ligand treatment for neurodegenerative diseases |
| WO2018183800A1 (en) * | 2017-03-30 | 2018-10-04 | Marquette University | Substituted (4'-hydroxyphenyl)cycloalkane and (4'-hydroxyphenyl)cycloalkene compounds and uses thereof as selective agonists of the estrogen receptor beta isoform for enhanced memory consolidation |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5990078A (en) * | 1995-07-14 | 1999-11-23 | The Trustees Of Columbia University In The City Of New York | Means of increasing estrogen receptor levels in neural tissue |
| FR2739777B1 (fr) * | 1995-10-11 | 1997-11-14 | Cird Galderma | Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose |
| WO1998021946A1 (en) * | 1996-11-18 | 1998-05-28 | Internutria, Inc. | Composition and treatment for persistent reproductive transition symptoms |
| US20040092010A1 (en) * | 2002-04-15 | 2004-05-13 | Ariel Ruiz I Altaba | Method of proliferating and inducing brain stem cells to differentiate to neurons |
| TR200102992T2 (tr) * | 1999-04-16 | 2004-12-21 | Astrazeneca Ab | ß östrojen reseptörü ligandları. |
| JP2004515496A (ja) * | 2000-12-07 | 2004-05-27 | アストラゼネカ・アクチエボラーグ | ベンズイミダゾール治療剤 |
| WO2002051821A1 (en) * | 2000-12-22 | 2002-07-04 | Astrazeneca Ab | Therapeutic compounds |
| US20030096264A1 (en) * | 2001-06-18 | 2003-05-22 | Psychiatric Genomics, Inc. | Multi-parameter high throughput screening assays (MPHTS) |
| DE60116109T2 (de) * | 2001-11-07 | 2006-09-07 | Schering Ag | In vitro Screening nach Liganden des Östrogenrezeptors |
| UA83620C2 (ru) * | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
| TWI306450B (en) * | 2001-12-13 | 2009-02-21 | Wyeth Corp | Substituted phenyl naphthalenes as estrogenic agents |
| TW200301107A (en) * | 2001-12-13 | 2003-07-01 | Wyeth Corp | Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents |
| US6774248B2 (en) * | 2001-12-18 | 2004-08-10 | Wyeth | Substituted 2-phenyl benzofurans as estrogenic agents |
| WO2004026290A1 (en) * | 2002-09-19 | 2004-04-01 | Merck & Co., Inc. | Method for treating depression and/or anxiety |
| CL2004000985A1 (es) * | 2003-05-16 | 2005-01-14 | Wyeth Corp | Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc |
| US7157492B2 (en) * | 2004-02-26 | 2007-01-02 | Wyeth | Dibenzo chromene derivatives and their use as ERβ selective ligands |
| JP2008505095A (ja) * | 2004-07-01 | 2008-02-21 | ワイス | エストロゲンリガンドとしての四環式化合物 |
-
2005
- 2005-12-15 RU RU2007120254/14A patent/RU2007120254A/ru not_active Application Discontinuation
- 2005-12-15 EP EP05854149A patent/EP1824478A2/en not_active Withdrawn
- 2005-12-15 MX MX2007007347A patent/MX2007007347A/es unknown
- 2005-12-15 US US11/304,037 patent/US20060135574A1/en not_active Abandoned
- 2005-12-15 KR KR1020077013666A patent/KR20070086329A/ko not_active Withdrawn
- 2005-12-15 AR ARP050105297A patent/AR051844A1/es unknown
- 2005-12-15 TW TW094144391A patent/TW200637545A/zh unknown
- 2005-12-15 AU AU2005316561A patent/AU2005316561A1/en not_active Abandoned
- 2005-12-15 CN CNA2005800434508A patent/CN101321524A/zh active Pending
- 2005-12-15 BR BRPI0519111-4A patent/BRPI0519111A2/pt not_active IP Right Cessation
- 2005-12-15 PA PA20058656601A patent/PA8656601A1/es unknown
- 2005-12-15 CA CA002590258A patent/CA2590258A1/en not_active Abandoned
- 2005-12-15 JP JP2007546887A patent/JP2008524236A/ja active Pending
- 2005-12-15 GT GT200500370A patent/GT200500370A/es unknown
- 2005-12-15 WO PCT/US2005/045375 patent/WO2006065968A2/en not_active Ceased
-
2006
- 2006-01-03 PE PE2006000026A patent/PE20061113A1/es not_active Application Discontinuation
-
2007
- 2007-05-24 NO NO20072658A patent/NO20072658L/no not_active Application Discontinuation
- 2007-05-31 IL IL183604A patent/IL183604A0/en unknown
- 2007-06-14 NI NI200700152A patent/NI200700152A/es unknown
- 2007-06-15 ZA ZA200705103A patent/ZA200705103B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0519111A2 (pt) | 2008-12-23 |
| CN101321524A (zh) | 2008-12-10 |
| PA8656601A1 (es) | 2006-12-07 |
| AR051844A1 (es) | 2007-02-14 |
| WO2006065968A8 (en) | 2008-09-12 |
| IL183604A0 (en) | 2007-10-31 |
| MX2007007347A (es) | 2007-07-13 |
| RU2007120254A (ru) | 2009-01-27 |
| NO20072658L (no) | 2007-09-12 |
| WO2006065968A2 (en) | 2006-06-22 |
| PE20061113A1 (es) | 2006-11-06 |
| CA2590258A1 (en) | 2006-06-22 |
| WO2006065968A3 (en) | 2008-04-10 |
| TW200637545A (en) | 2006-11-01 |
| GT200500370A (es) | 2006-07-13 |
| NI200700152A (es) | 2008-06-17 |
| KR20070086329A (ko) | 2007-08-27 |
| JP2008524236A (ja) | 2008-07-10 |
| EP1824478A2 (en) | 2007-08-29 |
| ZA200705103B (en) | 2009-11-25 |
| US20060135574A1 (en) | 2006-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101939017B (zh) | 大麻素在与抗精神病药物组合中的用途 | |
| AU2025201645A1 (en) | Methods and compositions for treating psychotic disorders | |
| Sorbera et al. | Pagoclone | |
| CN111032089A (zh) | 用于治疗应激相关障碍的组合物 | |
| JP2022507533A (ja) | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 | |
| Lladó-Pelfort et al. | Phencyclidine-induced disruption of oscillatory activity in prefrontal cortex: effects of antipsychotic drugs and receptor ligands | |
| EP2636414A1 (en) | Preventive or therapeutic agent for pain associated with herpes zoster in acute phase | |
| WO2007124348A2 (en) | Pharmacological modulation of positive ampa receptor modulator effects on neurotrophin expression | |
| US20060135574A1 (en) | Novel uses for estrogen beta agonists | |
| WO2008020651A1 (fr) | antagoniste de récepteur P2X4 | |
| KR20180100627A (ko) | 섬망의 예방 또는 치료제 | |
| US11318122B2 (en) | Pharmaceutical combination and its use for treating synucleinopathties | |
| KR20250155546A (ko) | 파킨슨병의 치료에 있어서의 메트포르민과 글리벤클라미드의 병용 | |
| JP2021505668A (ja) | 併用療法(睡眠障害およびcns障害)において使用するためのnmda受容体モジュレーター(ラパスチネル)の組合せ | |
| CN111973615A (zh) | 一种治疗躁狂型精神障碍及精神分裂症的药物 | |
| BR112021012491A2 (pt) | Combinações antineurodegenerativas de domperidona e uso | |
| CA2595208A1 (en) | Therapeutic agents for sensory disorders | |
| CA2659754A1 (fr) | Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3 | |
| Kramar | Experimental study of new 3-(2-R1-6-R2-4-oxyquinoline-3 (4H)-yl) alkyl (alkaryl-, aryl) carboxylic acid derivative (PC-66 compound) | |
| WO2000056292A2 (en) | Use of 1,2,4-triazolo[1,5-a]pyrimidine derivatives for treating migraine | |
| JP2023510173A (ja) | 中枢神経系障害の処置及び防止のための化合物 | |
| Adrien et al. | Neurobiology of insomnia | |
| KR20010029658A (ko) | 뇌의 아세틸콜린 방출 증강제 | |
| EA047023B1 (ru) | Композиции и способы лечения расстройств, связанных со стрессом | |
| OA21243A (en) | Compounds for treatment of alzheimer's disease. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |